Literature DB >> 25779465

Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer's disease.

Erika Droogsma1, Dieneke van Asselt1, Marjolein Diekhuis1, Nic Veeger2, Cornelis van der Hooft1, Peter Paul De Deyn3.   

Abstract

BACKGROUND: Some guidelines recommend to discontinue treatment with cholinesterase inhibitors (ChEIs) in patients with Alzheimer's disease (AD) without an initial response to ChEI treatment. Evidence supporting this recommendation, however, is limited. This study aimed to investigate the relation between the initial cognitive response to ChEI treatment and the subsequent long-term course of cognition of AD patients.
METHODS: The Frisian Alzheimer's Disease Cohort study is a retrospective longitudinal study of 576 community-dwelling AD patients treated with ChEIs in a "real-life" setting at a large memory clinic. A repeated measures analysis using a marginal model (population based averaged model) was applied to investigate whether there is a difference in the subsequent long-term course of cognition (Mini-Mental State Examination (MMSE)) between initial non-responders and responders. Absence of an initial response was defined as a lower MMSE score after the first six months of treatment compared to baseline, a positive response as the same or a higher MMSE score.
RESULTS: At baseline, median age was 80 years and the median MMSE score 23. Non-responders showed a slower rate of cognitive decline in the three subsequent years than responders, with a mean annual MMSE decline of 0.9 points versus 1.2 points, respectively (p < 0.0001).
CONCLUSIONS: Our results suggest that it is not appropriate to discontinue ChEI treatment solely based on the absence of an initial cognitive response.

Entities:  

Keywords:  Alzheimer's disease; cholinesterase inhibitors; course of cognition; longitudinal study; treatment response; “real-life” setting

Mesh:

Substances:

Year:  2015        PMID: 25779465     DOI: 10.1017/S1041610215000289

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  5 in total

1.  TREM2 variants and risk of Alzheimer's disease: a meta-analysis.

Authors:  Yanjun Lu; Wei Liu; Xiong Wang
Journal:  Neurol Sci       Date:  2015-06-03       Impact factor: 3.307

2.  Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review.

Authors:  Federico Emanuele Pozzi; Elisa Conti; Ildebrando Appollonio; Carlo Ferrarese; Lucio Tremolizzo
Journal:  Front Neurosci       Date:  2022-09-20       Impact factor: 5.152

3.  Extrapyramidal side effect of donepezil hydrochloride in an elderly patient: A case report.

Authors:  Hong-Chun Li; Ke-Xue Luo; Jie-Sheng Wang; Qin-Xian Wang
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

4.  Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers.

Authors:  Alice L La; Christine M Walsh; Thomas C Neylan; Keith A Vossel; Kristine Yaffe; Andrew D Krystal; Bruce L Miller; Elissaios Karageorgiou
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

5.  Responder Analysis of a Multicomponent Non-Pharmacological Intervention (MAKS) for People With Cognitive Impairment in the German Day-Care Study (DeTaMAKS).

Authors:  Katharina Luttenberger; Elmar Graessel; Elisa-Marie Behrndt; Dominik Özbe; Carolin Donath; Jennifer Scheel
Journal:  Front Psychiatry       Date:  2019-08-21       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.